Gender-Affirming Hormone Therapy Discontinuation is Uncommon
A study was conducted to examine risk and reasons for discontinuation of gender-affirming hormone therapy in transgender and gender diverse patients.
A study was conducted to examine risk and reasons for discontinuation of gender-affirming hormone therapy in transgender and gender diverse patients.
While Medicare covers a range of services, relatively high cost-sharing requirements exist for some beneficiaries, especially those with HIV.
Experts discuss strategies to reduce the maternal mortality gap by implementing implicit bias training and reevaluating clinical guidelines and algorithms.
ACOG experts provide actionable steps to reduce the maternal mortality crisis in the US, particularly among minority populations.